AlzChem Group Valuation

Is ACT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ACT (€57.8) is trading below our estimate of fair value (€211.69)

Significantly Below Fair Value: ACT is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACT?

Key metric: As ACT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ACT. This is calculated by dividing ACT's market cap by their current earnings.
What is ACT's PE Ratio?
PE Ratio11.8x
Earnings€50.10m
Market Cap€592.26m

Price to Earnings Ratio vs Peers

How does ACT's PE Ratio compare to its peers?

The above table shows the PE ratio for ACT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.4x
UZU Uzin Utz
10x2.1%€239.1m
2HRA H&R GmbH KGaA
13.1x34.8%€125.8m
NTG Nabaltec
8.9x5.7%€119.2m
WCH Wacker Chemie
29.5x38.0%€3.7b
ACT AlzChem Group
11.8x12.6%€592.3m

Price-To-Earnings vs Peers: ACT is good value based on its Price-To-Earnings Ratio (11.8x) compared to the peer average (15.4x).


Price to Earnings Ratio vs Industry

How does ACT's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ACT 11.8xIndustry Avg. 17.2xNo. of Companies11PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ACT is good value based on its Price-To-Earnings Ratio (11.8x) compared to the European Chemicals industry average (17.2x).


Price to Earnings Ratio vs Fair Ratio

What is ACT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.8x
Fair PE Ratio14.6x

Price-To-Earnings vs Fair Ratio: ACT is good value based on its Price-To-Earnings Ratio (11.8x) compared to the estimated Fair Price-To-Earnings Ratio (14.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€57.80
€72.05
+24.7%
4.3%€75.00€67.00n/a4
Nov ’25€52.20
€71.78
+37.5%
4.1%€75.00€67.00n/a4
Oct ’25€49.80
€61.30
+23.1%
7.9%€68.00€56.00n/a4
Sep ’25€48.20
€61.30
+27.2%
7.9%€68.00€56.00n/a4
Aug ’25€52.00
€54.05
+3.9%
8.7%€62.20€51.00n/a4
Jul ’25€47.70
€52.15
+9.3%
2.8%€54.60€51.00n/a4
Jun ’25€41.70
€49.40
+18.5%
11.3%€54.60€40.00n/a4
May ’25€45.80
€43.10
-5.9%
13.0%€52.00€37.00n/a4
Apr ’25€37.20
€43.10
+15.9%
13.0%€52.00€37.00n/a4
Mar ’25€27.50
€34.63
+25.9%
14.8%€40.00€29.00n/a4
Feb ’25€23.60
€34.63
+46.7%
14.8%€40.00€29.00n/a4
Jan ’25€25.60
€34.63
+35.3%
14.8%€40.00€29.00n/a4
Dec ’24€24.20
€33.00
+36.4%
12.4%€39.50€29.00n/a4
Nov ’24€21.90
€31.75
+45.0%
17.7%€39.50€24.00€52.204
Oct ’24€19.70
€30.33
+53.9%
13.0%€33.80€24.00€49.804
Sep ’24€20.40
€30.33
+48.7%
13.0%€33.80€24.00€48.204
Aug ’24€19.10
€30.33
+58.8%
13.0%€33.80€24.00€52.004
Jul ’24€18.30
€30.33
+65.7%
13.0%€33.80€24.00€47.704
Jun ’24€18.70
€30.20
+61.5%
12.7%€33.80€24.00€41.704
May ’24€19.15
€30.20
+57.7%
12.7%€33.80€24.00€45.804
Apr ’24€19.25
€30.20
+56.9%
12.7%€33.80€24.00€37.204
Mar ’24€19.70
€26.45
+34.3%
14.2%€31.30€21.00€27.504
Feb ’24€19.05
€25.20
+32.3%
22.6%€31.30€16.00€23.604
Jan ’24€15.90
€25.20
+58.5%
22.6%€31.30€16.00€25.604
Dec ’23€19.90
€25.20
+26.6%
22.6%€31.30€16.00€24.204
Nov ’23€16.40
€25.20
+53.7%
22.6%€31.30€16.00€21.904

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies